Final benefit of primary percutaneous coronary intervention for ST-elevation myocardial infarction in older patients: long-term results of a randomised trial

M.-J. de Boer; J P Ottervanger; A W J Van't Hof; J C A Hoorntje; H Suryapranata; F Zijlstra; Zwolle Myocardial Infarction Study Group

doi:10.1007/s12471-022-01724-5

Final benefit of primary percutaneous coronary intervention for ST-elevation myocardial infarction in older patients: long-term results of a randomised trial

M.-J. de Boer, J P Ottervanger^*, A W J Van't Hof, J C A Hoorntje, H Suryapranata, F Zijlstra, Zwolle Myocardial Infarction Study Group

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

BACKGROUND: Although the short-term benefit of primary percutaneous coronary intervention (PCI) in elderly patients with ST-elevation myocardial infarction (STEMI) has been demonstrated, the final long-term survival benefit is as yet unknown.

AIM: To assess the final survival benefit of primary PCI as compared to thrombolytic therapy in patients over 75 years of age.

METHODS: Patients > 75 years with STEMI were randomised to either primary PCI or thrombolysis. Long-term data on survival were available for all patients.

RESULTS: A total of 46 patients were randomised to primary PCI, 41 to thrombolysis. There were no significant differences in baseline variables. After a maximum of 20 years' follow-up, all patients had passed away. The patients randomised to thrombolysis died after a mean follow-up duration of 5.2 years (SD 4.9) compared to 6.7 years (SD 4.8) in patients randomised to primary PCI (p = 0.15). Thus, the mean final survival benefit of primary PCI was 1.5 years.

CONCLUSION: The final survival benefit of primary PCI as compared to thrombolysis in elderly patients with STEMI is 1.5 years and their life expectancy increases by 28.8%.

Original language	English
Pages (from-to)	567-571
Number of pages	5
Journal	Netherlands Heart Journal
Volume	30
Issue number	12
Early online date	16 Sept 2022
DOIs	https://doi.org/10.1007/s12471-022-01724-5
Publication status	Published - Dec 2022

Access to Document

10.1007/s12471-022-01724-5Licence: CC BY

Cite this

de Boer, M.-J., Ottervanger, J. P., Van't Hof, A. W. J., Hoorntje, J. C. A., Suryapranata, H., Zijlstra, F., & Zwolle Myocardial Infarction Study Group (2022). Final benefit of primary percutaneous coronary intervention for ST-elevation myocardial infarction in older patients: long-term results of a randomised trial. Netherlands Heart Journal, 30(12), 567-571. https://doi.org/10.1007/s12471-022-01724-5

@article{a84b047867934c03ad5176176ddce9b6,

title = "Final benefit of primary percutaneous coronary intervention for ST-elevation myocardial infarction in older patients: long-term results of a randomised trial",

abstract = "BACKGROUND: Although the short-term benefit of primary percutaneous coronary intervention (PCI) in elderly patients with ST-elevation myocardial infarction (STEMI) has been demonstrated, the final long-term survival benefit is as yet unknown.AIM: To assess the final survival benefit of primary PCI as compared to thrombolytic therapy in patients over 75 years of age.METHODS: Patients > 75 years with STEMI were randomised to either primary PCI or thrombolysis. Long-term data on survival were available for all patients.RESULTS: A total of 46 patients were randomised to primary PCI, 41 to thrombolysis. There were no significant differences in baseline variables. After a maximum of 20 years' follow-up, all patients had passed away. The patients randomised to thrombolysis died after a mean follow-up duration of 5.2 years (SD 4.9) compared to 6.7 years (SD 4.8) in patients randomised to primary PCI (p = 0.15). Thus, the mean final survival benefit of primary PCI was 1.5 years.CONCLUSION: The final survival benefit of primary PCI as compared to thrombolysis in elderly patients with STEMI is 1.5 years and their life expectancy increases by 28.8%.",

author = "{de Boer}, M.-J. and Ottervanger, {J P} and {Van't Hof}, {A W J} and Hoorntje, {J C A} and H Suryapranata and F Zijlstra and {Zwolle Myocardial Infarction Study Group}",

note = "{\textcopyright} 2022. The Author(s).",

year = "2022",

month = dec,

doi = "10.1007/s12471-022-01724-5",

language = "English",

volume = "30",

pages = "567--571",

journal = "Netherlands Heart Journal",

issn = "1568-5888",

publisher = "Bohn Stafleu van Loghum",

number = "12",

}

de Boer, M-J, Ottervanger, JP, Van't Hof, AWJ, Hoorntje, JCA, Suryapranata, H, Zijlstra, F & Zwolle Myocardial Infarction Study Group 2022, 'Final benefit of primary percutaneous coronary intervention for ST-elevation myocardial infarction in older patients: long-term results of a randomised trial', Netherlands Heart Journal, vol. 30, no. 12, pp. 567-571. https://doi.org/10.1007/s12471-022-01724-5

TY - JOUR

T1 - Final benefit of primary percutaneous coronary intervention for ST-elevation myocardial infarction in older patients

T2 - long-term results of a randomised trial

AU - de Boer, M.-J.

AU - Ottervanger, J P

AU - Van't Hof, A W J

AU - Hoorntje, J C A

AU - Suryapranata, H

AU - Zijlstra, F

AU - Zwolle Myocardial Infarction Study Group

PY - 2022/12

Y1 - 2022/12

N2 - BACKGROUND: Although the short-term benefit of primary percutaneous coronary intervention (PCI) in elderly patients with ST-elevation myocardial infarction (STEMI) has been demonstrated, the final long-term survival benefit is as yet unknown.AIM: To assess the final survival benefit of primary PCI as compared to thrombolytic therapy in patients over 75 years of age.METHODS: Patients > 75 years with STEMI were randomised to either primary PCI or thrombolysis. Long-term data on survival were available for all patients.RESULTS: A total of 46 patients were randomised to primary PCI, 41 to thrombolysis. There were no significant differences in baseline variables. After a maximum of 20 years' follow-up, all patients had passed away. The patients randomised to thrombolysis died after a mean follow-up duration of 5.2 years (SD 4.9) compared to 6.7 years (SD 4.8) in patients randomised to primary PCI (p = 0.15). Thus, the mean final survival benefit of primary PCI was 1.5 years.CONCLUSION: The final survival benefit of primary PCI as compared to thrombolysis in elderly patients with STEMI is 1.5 years and their life expectancy increases by 28.8%.

AB - BACKGROUND: Although the short-term benefit of primary percutaneous coronary intervention (PCI) in elderly patients with ST-elevation myocardial infarction (STEMI) has been demonstrated, the final long-term survival benefit is as yet unknown.AIM: To assess the final survival benefit of primary PCI as compared to thrombolytic therapy in patients over 75 years of age.METHODS: Patients > 75 years with STEMI were randomised to either primary PCI or thrombolysis. Long-term data on survival were available for all patients.RESULTS: A total of 46 patients were randomised to primary PCI, 41 to thrombolysis. There were no significant differences in baseline variables. After a maximum of 20 years' follow-up, all patients had passed away. The patients randomised to thrombolysis died after a mean follow-up duration of 5.2 years (SD 4.9) compared to 6.7 years (SD 4.8) in patients randomised to primary PCI (p = 0.15). Thus, the mean final survival benefit of primary PCI was 1.5 years.CONCLUSION: The final survival benefit of primary PCI as compared to thrombolysis in elderly patients with STEMI is 1.5 years and their life expectancy increases by 28.8%.

U2 - 10.1007/s12471-022-01724-5

DO - 10.1007/s12471-022-01724-5

M3 - Article

C2 - 36112340

SN - 1568-5888

VL - 30

SP - 567

EP - 571

JO - Netherlands Heart Journal

JF - Netherlands Heart Journal

IS - 12

ER -

Final benefit of primary percutaneous coronary intervention for ST-elevation myocardial infarction in older patients: long-term results of a randomised trial

Abstract

Access to Document

Fingerprint

Cite this